Dr. Shields is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4100 John R Street, HW04HO
Karmanos Cancer Institute
Detroit, MI 48201Phone+1 800-527-6266Fax+1 313-576-8767
Education & Training
- University of WashingtonFellowship, Hematology and Medical Oncology, 1981 - 1984
- University of WashingtonResidency, Internal Medicine, 1979 - 1981
- Massachusetts Institute of TechnologyPhD, Biology, 1973 - 1979
- Harvard Medical SchoolClass of 1979
Certifications & Licensure
- MI State Medical License 1995 - 2027
- WA State Medical License 1980 - 2002
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy Start of enrollment: 2007 Mar 30
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer Start of enrollment: 2009 Sep 01
- Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer Start of enrollment: 2010 Mar 08
- Join now to see all
Publications & Presentations
PubMed
- Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B-Southwest Oncology Group 80702 (Alliance).Justin C Brown, Chao Ma, Qian Shi, Felix Couture, Philip Kuebler
Journal of the National Cancer Institute. 2024-12-01 - Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy.Elisabeth Heath, Gregory Dyson, Jennifer R Ribeiro, Joanne Xiu, Kelsey Poorman
Cancer Research Communications. 2024-10-01 - Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancer.Jingyuan Wang, Joanne Xiu, Francesca Battaglin, Hiroyuki Arai, Shivani Soni
NPJ Precision Oncology. 2024-09-30
Press Mentions
- Karmanos Cancer Institute Physicians Begin Prescribing New FDA-Approved Radiofrequency Electromagnetic Device to Treat Advanced Liver CancerDecember 18th, 2024
- Karmanos Cancer Institute Receives $630,000 CATCH-UP Grant to Recruit Minority and Rural Patients to Clinical TrialsAugust 25th, 2020
- OncLive® Presents State of the Science Summit™ on Gastrointestinal MalignanciesApril 23rd, 2019
- Join now to see all
Grant Support
- Imaging Cellular Stress And Treatment Response Using Positron Emission TomographyNational Cancer Institute2010–2012
- Develpmental TherapeuticsNational Cancer Institute2005–2009
- Labeled Thymidine -- Development As A PET Imaging AgentNational Cancer Institute2004–2008
- Labeled Thymidine-Development As A PET Imaging AgentNational Cancer Institute2005–2006
- Midcareer Investigator AwardNational Cancer Institute1999–2003
- Labeled Thymidine--Development As A PET Imaging AgentNational Cancer Institute1997–2003
- Developmental TherapeuticsNational Cancer Institute2001–2002
- PET Imaging Of Drug Kinetics And PathwaysNational Cancer Institute1999–2002
- Metabolic Measurement In Lymphoma Treated With ChemotherapyNational Cancer Institute1996–1997
- Labeled Thymidine--Development As A PET Imaging AgentNational Cancer Institute1988–1994
- Labeled Thymidine: Development As A PET Imaging AgentNational Cancer Institute1987–1993
- Labeled Thymidine--Development As A PET Imaging AgentNational Cancer Institute1985–1987
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: